Reforgene wins Emerging Biotech with the Most Investment Potential of the Year
The 2021 Second Biotech Industry Annual Climbing List was announced on November 11. With its leading strength in innovative gene editing medicines, Reforgene won the "Most Investment-Worthy Emerging BioTech of the Year" award. A total of five enterprises were selected, including Inmagene Biopharmaceuticals and HemaCell, among others.
The selection was evaluated by East China University of Science and Technology, the Shanghai Society of Bioengineering, the Shanghai Society of Microbiology and BioValley, together with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, the Shanghai Biomedical Industry Association, Caitong Securities, the Insight database, the journal Progress in Pharmaceutical Sciences and Firestone.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com · BD@reforgene.com